UBS Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $367K | Sell |
2,000
-74,500
| -97% | -$13.7M | ﹤0.01% | 6289 |
|
|
2025
Q4 | $13.5M | Buy |
76,500
+7,900
| +12% | +$1.29M | ﹤0.01% | 2981 |
|
|
2025
Q3 | $9.61M | Buy |
68,600
+1,500
| +2% | +$203K | ﹤0.01% | 3330 |
|
|
2025
Q2 | $8.43M | Sell |
67,100
-31,900
| -32% | -$3.97M | ﹤0.01% | 3267 |
|
|
2025
Q1 | $13.5M | Sell |
99,000
-198,000
| -67% | -$28.3M | ﹤0.01% | 2745 |
|
|
2024
Q4 | $45.4M | Buy |
297,000
+138,500
| +87% | +$23.4M | 0.01% | 1548 |
|
|
2024
Q3 | $30.7M | Sell |
158,500
-400
| -0.3% | -$83.7K | 0.01% | 1498 |
|
|
2024
Q2 | $36.8M | Sell |
158,900
-13,900
| -8% | -$3.02M | 0.01% | 1238 |
|
|
2024
Q1 | $37.3M | Sell |
172,800
-86,700
| -33% | -$20.3M | 0.01% | 1234 |
|
|
2023
Q4 | $67.2M | Sell |
259,500
-6,400
| -2% | -$1.57M | 0.02% | 794 |
|
|
2023
Q3 | $68.3M | Buy |
265,900
+118,700
| +81% | +$31.7M | 0.02% | 668 |
|
|
2023
Q2 | $41.9M | Buy |
147,200
+11,200
| +8% | +$3.33M | 0.01% | 931 |
|
|
2023
Q1 | $37.8M | Sell |
136,000
-30,700
| -18% | -$8.49M | 0.01% | 937 |
|
|
2022
Q4 | $46.2M | Buy |
166,700
+14,100
| +9% | +$3.98M | 0.02% | 848 |
|
|
2022
Q3 | $40.7M | Buy |
152,600
+17,500
| +13% | +$3.72M | 0.02% | 803 |
|
|
2022
Q2 | $27.6M | Buy |
135,100
+17,600
| +15% | +$3.6M | 0.01% | 1111 |
|
|
2022
Q1 | $24.7M | Sell |
117,500
-138,000
| -54% | -$30M | 0.01% | 1278 |
|
|
2021
Q4 | $61.3M | Buy |
255,500
+13,034
| +5% | +$3.35M | 0.02% | 843 |
|
|
2021
Q3 | $68.6M | Sell |
242,466
-26,900
| -10% | -$8.82M | 0.02% | 703 |
|
|
2021
Q2 | $93.3M | Buy |
269,366
+51,000
| +23% | +$15.5M | 0.03% | 547 |
|
|
2021
Q1 | $61.1M | Buy |
218,366
+36,366
| +20% | +$9.81M | 0.02% | 727 |
|
|
2020
Q4 | $44.6M | Buy |
182,000
+26,700
| +17% | +$6.89M | 0.02% | 845 |
|
|
2020
Q3 | $44.1M | Sell |
155,300
-70,000
| -31% | -$19.5M | 0.02% | 707 |
|
|
2020
Q2 | $60.3M | Buy |
225,300
+2,000
| +0.9% | +$601K | 0.03% | 532 |
|
|
2020
Q1 | $70.6M | Buy |
223,300
+78,900
| +55% | +$23.9M | 0.03% | 440 |
|
|
2019
Q4 | $42.8M | Sell |
144,400
-6,200
| -4% | -$1.72M | 0.01% | 860 |
|
|
2019
Q3 | $35.1M | Buy |
150,600
+50,000
| +50% | +$11.6M | 0.01% | 879 |
|
|
2019
Q2 | $23.5M | Sell |
100,600
-21,000
| -17% | -$4.85M | 0.01% | 1109 |
|
|
2019
Q1 | $28.7M | Buy |
121,600
+77,100
| +173% | +$24.3M | 0.01% | 926 |
|
|
2018
Q4 | $13.4M | Buy |
44,500
+19,500
| +78% | +$6.22M | 0.01% | 1364 |
|
|
2018
Q3 | $8.83M | Hold |
25,000
| – | – | ﹤0.01% | 1880 |
|
|
2018
Q2 | $7.26M | Buy |
25,000
+10,000
| +67% | +$2.81M | ﹤0.01% | 2004 |
|
|
2018
Q1 | $4.11M | Sell |
15,000
-5,000
| -25% | -$1.55M | ﹤0.01% | 2494 |
|
|
2017
Q4 | $6.37M | Sell |
20,000
-900
| -4% | -$289K | ﹤0.01% | 2114 |
|
|
2017
Q3 | $6.54M | Buy |
20,900
+16,030
| +329% | +$4.75M | ﹤0.01% | 1958 |
|
|
2017
Q2 | $1.32M | Buy |
4,870
+670
| +16% | +$177K | ﹤0.01% | 3366 |
|
|
2017
Q1 | $1.15M | Sell |
4,200
-29,800
| -88% | -$8.43M | ﹤0.01% | 3415 |
|
|
2016
Q4 | $9.64M | Sell |
34,000
-227,600
| -87% | -$67.5M | 0.01% | 1526 |
|
|
2016
Q3 | $81.9M | Buy |
261,600
+220,444
| +536% | +$65.3M | 0.05% | 373 |
|
|
2016
Q2 | $9.95M | Sell |
41,156
-35,800
| -47% | -$9.43M | 0.01% | 1389 |
|
|
2016
Q1 | $20M | Sell |
76,956
-45,793
| -37% | -$12.1M | 0.01% | 886 |
|
|
2015
Q4 | $37.6M | Buy |
122,749
+35,800
| +41% | +$10.3M | 0.02% | 619 |
|
|
2015
Q3 | $25.4M | Sell |
86,949
-31,051
| -26% | -$10.3M | 0.02% | 758 |
|
|
2015
Q2 | $47.7M | Buy |
118,000
+92,500
| +363% | +$37.1M | 0.03% | 542 |
|
|
2015
Q1 | $10.8M | Sell |
25,500
-26,400
| -51% | -$10.4M | 0.01% | 1414 |
|
|
2014
Q4 | $17.6M | Buy |
+51,900
| New | +$16.8M | 0.01% | 1083 |
|
Other funds holding BIIB
VCM
VPM
UBS Group's BIIB Position: Q1 2026 in Review
UBS Group reduced its Biogen (BIIB) stake by 18% in Q1 2026, selling an estimated $21.8M and leaving 523,450 shares worth $96M. The position accounts for 0.01% of the portfolio, ranked #1083.
UBS Group first reported a position in BIIB in Q4 2014 and has held it in 46 quarters since. The position peaked at $160M in Q4 2024. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- UBS Group held 523,450 shares of Biogen worth $96M as of Q1 2026.
- UBS Group sold 118,338 Biogen shares in Q1 2026, an estimated $21.8M.
- Biogen made up 0.01% of UBS Group's portfolio in Q1 2026, its #1083 holding.
- UBS Group first reported a position in Biogen in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Biogen position peaked at $160M in Q4 2024.
- 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.